EX-10.3



 Exhibit 10.3 

CONFIDENTIAL TREATMENT REQUESTED 

AMENDMENT 1 

TO THE 

RESEARCH COLLABORATION AND 

LICENSE AGREEMENT 

by and between 
 F. Hoffmann-La Roche Ltd 
 with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland
(“Roche Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey
07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”) 
 on the one hand 

and 
 Pieris Pharmaceuticals GmbH 

with an office and place of business at Lise-Meitner-Str. 30, 83534 Freising, Germany (“Pieris
Freising”) 
 and 
 Pieris
Pharmaceuticals, Inc. 
 with an office and place of business at 255 State Street, 9th Floor,
Boston, MA 02109, USA (“Pieris US”; Pieris Freising and Pieris US together referred to as “Pieris”) 
 on the other hand.

  

			
	WHEREAS,	  	Roche and Pieris entered on December 8, 2015, into a Research Collaboration and License Agreement (hereinafter called “AGREEMENT”) to work together to develop binders that inhibit or specifically bind to [***]
using Pieris Technology and Roche’s [***] for application in particular in cancer;
		
	WHEREAS,	  	Roche and Pieris are willing to amend the AGREEMENT in accordance with Section 21.10 with this amendment (hereinafter called “AMENDMENT 1”) in order to prolong the Research Term;
		
	THEREFORE,	  	the parties hereto agree to amend the AGREEMENT as follows:









 CONFIDENTIAL TREATMENT REQUESTED 

 


	I.	The wording in Section 3.1.4 of the AGREEMENT shall be deleted and replaced by the following: 


3.1.4    Research Term 

The Research Term shall commence on January 1, 2016 and shall continue until January 1, 2018 unless extended by Roche by providing
written notice (including via e-mail) to Pieris no later than September 30, 2017 to prolong the Research Term to continue until April 30, 2018. In the event that Roche opts to prolong the Research
term to continue until April 30, 2018, Roche may further extend the Research Term to continue until August 31, 2018 by providing written notice (including via email) to Pieris no later than January 31, 2018. If at the end of the
Research Term (including any extension(s)) the original objectives of the Research Plan are not met and Roche is unable to choose Selected Binders for product development, the Parties may agree on whether to further extend the Research Term and the
share of funding to be contributed by each Party. 
  

	II.	The AMENDMENT 1 will come into effect on May 31, 2017. 

  

	III.	All other terms and conditions of the AGREEMENT remain unchanged and in full force and effect, and capitalized terms used in this AMENDMENT 1 shall have the meaning as defined in the AGREEMENT unless otherwise defined
in this AMENDMENT 1. 

 Agreed by the parties through their authorized representatives: 

 

			
		 	 Pieris Pharmaceuticals GmbH
  

/s/ Stephen S. Yoder

	Name:	 	Stephen S. Yoder
	Title:	 	Managing Director
		
		 	 Pieris Pharmaceuticals, Inc.
  

/s/ Stephen S. Yoder

	Name:	 	Stephen S. Yoder
	Title:	 	President and CEO

  

									
		 	 F. Hoffmann-La Roche Ltd

 
 /s/ Dr. Barbara Lueckel
	 		  		  	  
  

/s/ Dr. Christof Burri

	Name:	 	Dr. Barbara Lueckel	 		  	Name:	  	Dr. Christof Burri
	Title:	 	Head of Early Stage Partnering	 		  	Title:	  	Legal Counsel

 Hoffmann-La Roche Inc. 

  
 Portions of the
exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 2/3 









 CONFIDENTIAL TREATMENT REQUESTED 

 

  

			
		 	 /s/ John P. Parise

	Name:	 	John P. Parise
	Title:	 	Authorized Signatory


  
 Portions of the
exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 3/3